Dyne Therapeutics reported Q3 financials and announced its z-rostudirsen BLA received FDA priority review with a PDUFA date of Jan 2027, marking a critical regulatory step for the treatment of Duchenne muscular dystrophy.
Dyne Therapeutics reported Q3 financials and announced its z-rostudirsen BLA received FDA priority review with a PDUFA date of Jan 2027, marking a critical regulatory step for the treatment of Duchenne muscular dystrophy.